Search - tctmd.com

Displaying 941 - 960 of 1914

Sort: Relevancy | Date

News Daily News

Yet Another Study Underscores Drawbacks of Risk-Adjusted Mortality as a Measure of PCI Quality

Todd Neale

April 04, 2017

News Daily News

‘Constellation of Cardiovascular Stressors’ Puts Firefighters at Risk for MI

L.A. McKeown

April 03, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

Todd Neale

March 28, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

The Numbers Game: Door-to-Balloon or First Medical Contact? STEMI Care Still Needs Work Nationwide

L.A. McKeown

March 16, 2017

News Daily News

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

L.A. McKeown

March 14, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Deserved or Not, Public Reports on Underperforming PCI Hospitals Improves Performance

Yael L. Maxwell

March 07, 2017

News Daily News

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Shelley Wood

March 06, 2017

News Daily News

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Yael L. Maxwell

March 03, 2017

News Daily News

Prior Cancer and Chest Radiation Not Associated With Worse PCI Outcomes

L.A. McKeown

February 27, 2017

Advertisement

Yet Another Study Underscores Drawbacks of Risk-Adjusted Mortality as a Measure of PCI Quality

‘Constellation of Cardiovascular Stressors’ Puts Firefighters at Risk for MI

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

The Numbers Game: Door-to-Balloon or First Medical Contact? STEMI Care Still Needs Work Nationwide

‘Hub and Spoke’ Model Promises to Improve Access to PCI for STEMI in Low- and Middle-Income Countries

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Deserved or Not, Public Reports on Underperforming PCI Hospitals Improves Performance

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Mixed Clinical, Biomarker Score Might Boost CAD Risk Prediction

Prior Cancer and Chest Radiation Not Associated With Worse PCI Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content